null

null

null

null

null

null

null

null

null

Minimal debt; BeyondSpring is primarily equity-financed with cash burn from R&D; a 20bp rate rise has negligible interest expense impact.

Low sensitivity; company holds cash/equivalents and carries little to no interest-bearing debt, so rate moves affect yield on cash reserves marginally.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) Chinese API/active pharmaceutical ingredient sourcing subject to US-China trade restrictions; 2) US FDA/regulatory approval pathway as single-country chokepoint.

Primary markets are US and China; RMB/USD devaluation risk is significant given China-based operations and CNY-denominated costs versus USD reporting currency.

Operations split between US (clinical/regulatory) and China (manufacturing/R&D); heavily exposed to CNY depreciation and US-China geopolitical tensions.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Plinabulin synthesis relies on a limited number of Chinese CMOs; single-source API manufacturing represents a non-substitutable critical dependency above 30% threshold.

Biopharmaceutical drug developer; cloud infrastructure termination would disrupt data/trial management but not core drug development or manufacturing operations.

Secondary risk: clinical trial data platforms and electronic data capture systems could face disruption; ~2–4 weeks to migrate trial databases to alternative infrastructure.

Moderate API/platform coupling risk in clinical data systems; core IP (plinabulin) is proprietary and not platform-dependent, limiting overall switching cost exposure.

Revenue model is drug sales/licensing — not an investment contract; Howey Test risk is negligible; equity securities not structured as profit-sharing instruments.

Very High

Significant: clinical trial patient data collected across US and China creates GDPR (if EU trials expand) and HIPAA exposure; CCPA applies to US patient data handling.

Low antitrust risk; BeyondSpring is a small-cap oncology biotech with no dominant market share; no pricing or market allocation conduct triggering scrutiny.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly pre-revenue/transactional; commercial revenue depends on plinabulin approval; current revenue from limited licensing deals is non-recurring.

Drug commercialization (product sales) and partnership/licensing fees; no subscription component; revenue is milestone- and approval-contingent.

Oncology drug pricing subject to CMS negotiation pressure and competitive G-CSF market; plinabulin differentiation on dual mechanism may support modest premium pricing.

Moderate; oncology supportive care drugs face biosimilar and generic G-CSF competition; differentiated mechanism provides limited but real pricing leverage.

Target gross margin 70–80% at commercial scale, consistent with specialty oncology drug peers, assuming CMO manufacturing costs normalize post-launch.

No free-rider risk; pharmaceutical product requires prescription and purchase; however, physician adoption stickiness is moderate given competitive alternatives.

Revenue growth is sublinear to headcount post-approval; commercialization requires a sales force build, but manufacturing is outsourced, limiting linear headcount scaling.

Marginal cost of growth is primarily COGS (CMO manufacturing) and sales force; at 10x revenue scale, gross margins improve as fixed R&D costs are amortized.

null

Customer acquisition via oncologist detailing; at 10x scale, CAC rises linearly with sales rep headcount but LTV per prescriber improves with repeat oncology use.

No meaningful network effects; pharmaceutical adoption is driven by clinical evidence and physician relationships, not user-base scale dynamics.

-33.3% Return on Assets (Negative equity)

High recession resistance; cancer supportive care drugs are non-discretionary; oncology treatment demand is largely inelastic to economic cycles.

Oncologists and hospital/cancer center formulary committees prescribing supportive care agents during chemotherapy.

Specialty distributors and group purchasing organizations (GPOs) controlling hospital drug procurement; concentration risk if major GPO excludes plinabulin.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital allocated to clinical trials and regulatory filings, not legacy infrastructure; minimal capex model as manufacturing is outsourced to CMOs in China.

0001677940

BYSI